Fast-forwarding hit to lead: aurora and epidermal growth factor receptor kinase inhibitor lead identification.

Article Details

Citation
Copy to clipboard

Coumar MS, Chu CY, Lin CW, Shiao HY, Ho YL, Reddy R, Lin WH, Chen CH, Peng YH, Leou JS, Lien TW, Huang CT, Fang MY, Wu SH, Wu JS, Chittimalla SK, Song JS, Hsu JT, Wu SY, Liao CC, Chao YS, Hsieh HP

Fast-forwarding hit to lead: aurora and epidermal growth factor receptor kinase inhibitor lead identification.

J Med Chem. 2010 Jul 8;53(13):4980-8. doi: 10.1021/jm1000198.

PubMed ID
20550212 [ View in PubMed
]
Abstract

A focused library of furanopyrimidine (350 compounds) was rapidly synthesized in parallel reactors and in situ screened for Aurora and epidermal growth factor receptor (EGFR) kinase activity, leading to the identification of some interesting hits. On the basis of structural biology observations, the hit 1a was modified to better fit the back pocket, producing the potent Aurora inhibitor 3 with submicromolar antiproliferative activity in HCT-116 colon cancer cell line. On the basis of docking studies with EGFR hit 1s, introduction of acrylamide Michael acceptor group led to 8, which inhibited both the wild and mutant EGFR kinase and also showed antiproliferative activity in HCC827 lung cancer cell line. Furthermore, the X-ray cocrystal study of 3 and 8 in complex with Aurora and EGFR, respectively, confirmed their hypothesized binding modes. Library construction, in situ screening, and structure-based drug design (SBDD) strategy described here could be applied for the lead identification of other kinases.

DrugBank Data that Cites this Article

Binding Properties
DrugTargetPropertyMeasurementpHTemperature (°C)
AfatinibEpidermal growth factor receptorIC 50 (nM)11N/AN/ADetails
GefitinibEpidermal growth factor receptorIC 50 (nM)20N/AN/ADetails